Journal
FEMS MICROBIOLOGY REVIEWS
Volume 31, Issue 1, Pages 3-14Publisher
OXFORD UNIV PRESS
DOI: 10.1111/j.1574-6976.2006.00051.x
Keywords
Neisseria meningitidis; meningitis; vaccines
Categories
Funding
- NIAID NIH HHS [AI33517-10, AI40247-06] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040247, R01AI040247, R01AI033517] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Since the first outbreaks of meningococcal meningitis were first described in Geneva in 1804 and in New England in 1806, and since the discovery of the causative agent by Weichselbaum in 1887 and the beginning of epidemics of meningococcal meningitis in the sub-Saharan Africa similar to 100 years ago, Neisseria meningitidis has been recognized as the cause worldwide of epidemic meningitis and meningococcemia. The massive epidemic outbreaks in sub-Saharan Africa in the 1990's, the emergence since 1995 of serogroups Y, W-135 and X and the prolonged outbreak of serogroup B meningococcal disease in New Zealand over the last decade serve to remind us of the continued potential of the meningococcus to cause global morbidity and mortality. This report reviews new discoveries impacting prevention and future prospects for conquering the meningococcus as a human pathogen.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available